After the emergence of more controversial information of Avandia that it increasing the chances of heart diseases, 20 out of 33 of the U. S. Food and Drug Administration experts voted, on Wednesday, in favor of the GlaxoSmithKline's diabetes drug staying available on the markets, without any restrictions.

They justified their decision saying that the information introduced regarding the heart risks caused by Avandia, was not decisive enough, and that the experts cannot take away a medicine used by hundreds of patients in need of it, on ill-founded grounds and doubts.

The FDA 's support of Avandia to remain on the market, until any further information appear on the surface, allowed GlaxoSmithKline GSK to reassess the Company's capability to cover the $460 million to cover legal expenses and settle a liability law suit related to the drug. The FDA settled for the idea of carrying on some clinical trials to test Avandia's side effects. Same tests were carried out in 2007, and resulted in the drug being safe for public use.

For GlaxoSmithKline, it stated, "We believe that when used in the appropriate patient and in accordance with labeling, Avandia is a safe and effective treatment option for type 2 diabetes".